ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXPLORES HOW TO MAKE PATIENTS AS PARTNERS IN RESEARCH A REALITY

Published May 24, 2016
Washington, DC—May 24, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Workshop 13—Patients as Partners in Research—Making It a Reality—was held this afternoon in Washington, DC, USA. The Workshop discussion leaders included:
  • Rachel Harrington, PhD, Senior Research Alliances Manager, Health Economics and Clinical Outcomes Research, Astellas Medical Affairs Americas, Northbrook, IL, USA
  • Alfonso Aguarón, Project Manager, Myeloma Patients Europe, Madrid, Spain
  • Robert N. McBurney, PhD, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA
  • Holly Peay, PhD, MS, CGC, Principal Investigator, DuchenneConnect Network, Parent Project Muscular Dystrophy, and Research Scientist, RTI International, Research Triangle Park, NC, USA
Including the perspective of patients and their representatives in all stages of the research and decision making process has become increasingly important. This type of patient engagement has been cited by researchers, government agencies, and patient advocates as an essential step to improve health care delivery and outcomes. The discussion leaders provided an overview of the key components that are essential for patient engagement and collaboration in clinical research studies and in health care decision making. Engagement components range from low-level interaction through consultation to higher level collaboration through partnership and shared leadership. Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC. ###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×